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Abstract
Introduction: Signaling downstream of Ras is mediated by three major pathways, Raf/ERK, phosphatidylinositol
3 kinase (PI3K), and Ral guanine nucleotide exchange factor (RalGEF). Ras signal transduction pathways play an
important role in breast cancer progression, as evidenced by the frequent over-expression of the Ras-activating
epidermal growth factor receptors EGFR and ErbB2. Here we investigated which signal transduction pathways
downstream of Ras contribute to EGFR-dependent transformation of telomerase-immortalized mammary
epithelial cells HME16C. Furthermore, we examined whether a highly transcriptionally regulated ERK pathway
target, PHLDA1 (TDAG51), suggested to be a tumor suppressor in breast cancer and melanoma, might modulate
the transformation process.
Methods: Cellular transformation of human mammary epithelial cells by downstream Ras signal transduction
pathways was examined using anchorage-independent growth assays in the presence and absence of EGFR
inhibition. TDAG51 protein expression was down-regulated by interfering small hairpin RNA (shRNA), and the
effects on cell proliferation and death were examined in Ras pathway-transformed breast epithelial cells.
Results: Activation of both the ERK and PI3K signaling pathways was sufficient to induce cellular transformation,
which was accompanied by up-regulation of EGFR ligands, suggesting autocrine EGFR stimulation during the
transformation process. Only activation of the ERK pathway was sufficient to transform cells in the presence of
EGFR inhibition and was sufficient for tumorigenesis in xenografts. Up-regulation of the PHLDA1 gene product,
TDAG51, was found to correlate with persistent ERK activation and anchorage-independent growth in the
absence or presence of EGFR inhibition. Knockdown of this putative breast cancer tumor-suppressor gene
resulted in increased ERK pathway activation and enhanced matrix-detached cellular proliferation of Ras/Raf
transformed cells.
Conclusion:  Our results suggest that multiple Ras signal transduction pathways contribute to mammary
epithelial cell transformation, but that the ERK signaling pathway may be a crucial component downstream of
EGFR activation during tumorigenesis. Furthermore, persistent activation of ERK signaling up-regulates TDAG51.
This event serves as a negative regulator of both Erk activation as well as matrix-detached cellular proliferation
and suggests that TDAG51 opposes ERK-mediated transformation in breast epithelial cells.
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Background
The development and progression of breast cancer is the
result of multiple genetic changes, which lead to complex
alterations in signal transduction networks in breast can-
cer cells relative to their normal epithelial counterparts.
Signaling differences between tumor and normal cells are
reflected in altered gene expression patterns, a finding that
has been widely investigated using various molecular
techniques. Patterns of differential gene expression have
been used for classification and prognostication of certain
cancers and may be valuable for prospectively predicting
responsiveness to therapeutic treatments [1]. In addition
to serving as biomarkers, some differentially expressed
gene products have been informative in defining the phys-
iological differences between normal and cancer cells. In
order to understand the impact of dysregulated signaling
pathways upon gene expression and function, it is neces-
sary to connect differential gene expression to upstream
signaling pathways.
Ras activation is a common intermediary in signaling
pathways initiated by a variety of cell surface receptors,
and signaling pathways downstream of Ras have been
implicated repeatedly in oncogenesis. Ras proteins are fre-
quently mutated to an activated form in human cancers,
particularly in tumors of the pancreas, colon, thyroid, and
lung [2]. Ras mutations are rare in breast cancer, where the
mutation rate is less than 5% [3]. However, Ras signaling
is hyperactive in many primary breast tumors [4]. This is
most likely due to the activation of growth factor receptors
that activate Ras exchange factors, such as the epidermal
growth factor receptors EGFR (ErbB1) and ErbB2 (HER2/
neu) and the colony stimulating factor-1 (CSF-1) receptor
c-fms [5,6]. EGFR and ErbB2 receptor over-expression
occurs in one quarter to one-half of all breast tumors, and
this correlates with a significantly decreased disease-free
and overall survival rates [5,7]. In addition, ligands for the
EGFR such as transforming growth factor-a, amphiregu-
lin, epiregulin, betacellulin, and heparin-binding EGF
stimulate the receptor in primary breast tumors to
enhance local growth and progression of the disease [8].
Finally, activating mutations in the PI3K pathway, an
immediate downstream effector of Ras, occur in a subset
of breast tumors [9,10]. Taken together, these findings
suggest that breast cancer is a relevant model in which to
study the biology of downstream Ras signal transduction.
The Ras oncogene binds numerous effectors that in turn
activate a variety of signaling pathways. The most highly
characterized of these are the Raf proteins, PI3K, and the
Ral guanidine nucleotide exchange factors (RalGEFs),
although Ras does recruit and activate other potentially
transforming effectors [11]. The dissection of individual
Ras signaling pathways is possible using effector domain
mutants (EDMs) of Ras, for which single amino acid
mutations in the effector binding domain allow the bind-
ing and activation of specific effectors, but not others [12].
These Ras EDMs, together with activated or dominant-
negative versions of downstream effectors, have been used
to characterize the pathways that contribute to the trans-
formation of immortalized cells.
In mammary epithelial cells, both species- as well as cell
line-dependent differences in Ras downstream signaling
pathways have been found to induce tumorigenesis and/
or anchorage-independent growth, a measure of in vitro
transformation. Studies using immortalized mouse EpH4
mammary epithelial cells have implicated Raf as well as
PI3K pathways in supporting transformation and tumori-
genesis [13]. For human immortalized mammary epithe-
lial cells, Raf and PI3K clearly contribute to
transformation, although each is usually not sufficient for
tumor formation in animal models [14,15]. In fact, the
immortalized human breast epithelial cell line HMLE
required simultaneous activation of Raf, PI3K, and the
RalGEF pathways for maximal anchorage-independent
growth and tumorigenic transformation [14].
Dissecting the physiological consequences of individual
Ras-mediated signaling pathways with respect to mam-
mary epithelial transformation is of obvious interest. The
ability of activated Ras and Raf to induce autocrine expres-
sion of epidermal-like growth factors has been implicated
in the protection of MCF10A mammary epithelial cells
from anoikis [16]. Using HMEC16C cells, a telomerase-
immortalized human mammary epithelial cell line, we
have investigated the contribution of EGFR signaling to
anchorage-independent growth initiated by Raf and addi-
tional signaling pathways downstream of Ras. We deter-
mined that ERK but not PI3K or RalGEF activation of
HMEC16C cells supports anchorage independent prolif-
eration independent of EGFR activation.
We performed a functional analysis of one gene in partic-
ular, TDAG51, whose expression is regulated by ERK
through EGFR dependent and independent mechanisms.
The loss of TDAG51 mRNA and protein has been corre-
lated with breast adenocarcinoma and melanoma pro-
gression in clinical samples [17,18]. The importance of
TDAG51 regulation on the transformed phenotype of Ras-
infected cells was addressed using TDAG51-specific inter-
fering small hairpin RNA (shRNA) to reduce TDAG51 lev-
els. Consistent with a tumor suppressor role, loss of
TDAG51 increased ERK-mediated cellular proliferation.
Methods
Culture of human epithelial cell lines
HME16C human mammary cells [19] were cultured in
Clonetics Mammary Epithelial Basal Media (MEBM) with
MEGM SingleQuot supplements (Cambrex), and HEK-HTBMC Cancer 2008, 8:189 http://www.biomedcentral.com/1471-2407/8/189
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human embryonic kidney epithelial cells [20] in DMEM
(Invitrogen) plus 10% fetal bovine serum (Invitrogen).
All cells were maintained at 37°C and 5% CO2. For induc-
tion of proteins from the tetracycline-inducible retroviral
expression vector pLRT, 250 ng/mL of doxycycline
(Sigma-Aldrich) was added to culture media.
Retroviral and lentiviral constructs and infections
Constructs for the inducible expression of H-Ras, H-Ras
effector domain mutants, and Rlf-CAAX were created by
PCR subcloning the sequences of HA-tagged H-RasG12V
(RasV12), H-RasG12V, E37G (RasV12G37), H-RasG12V,
T35S (RasV12S35), H-RasG12V, Y40C (RasV12C40), and Rlf-
CAAX [21] into the tetracycline-inducible retroviral
expression vector pLRT [22]. The generation of retrovi-
ruses and lentiviruses was as described [23]. Polyclonal
populations of pLRT infected cells were selected with 5
μg/mL blasticidin. The expression of the anti-TDAG51
shRNA 36-1 was accomplished by sub-cloning the anti-
TDAG51 shRNA sequence 5'-
GGAACTGCACTTCTCCAACTTCAAGAGAGTTGGA-
GAAGTGCAGTTCCTTTTT-3' into the pLVTHM lentivirus
(kindly provided by Dr. D. Trono, Lausanne, Switzerland;
[24]). After infection, cells with integrated lentivirus were
selected by sterile sorting for GFP. Three sterile sorts were
performed to acquire a polyclonal population of cells
exclusively expressing GFP that was subsequently exam-
ined for TDAG51 protein reduction by western blotting.
Western blotting and Ral activation assays
Western blots were performed using Chemilluminescence
(Pierce). Antibodies used for western blots included anti-
Ras mAb (BD Biosciences, cat#R02120), rat anti-HA mAb
(Roche, cat#1988506), anti-phospho Erk mAb (Santa
Cruz, cat#sc-7383), goat anti- Erk2 (Santa Cruz, C14-G,
cat#154-G), rabbit anti-phospho-Akt Ser473 (Cell Signal-
ing Technology), goat anti-Akt (Santa Cruz, C-20, cat#sc-
1618), or an anti-alpha tubulin mAb (clone DM1A, Neo-
Markers), followed by detection using appropriate anti-
mouse, rabbit, or goat HRP-conjugated secondary anti-
bodies (Jackson Labs) and ECL detection. For Ral activa-
tion assays, the Ral Activation Assay Kit (Upstate Cell
Signaling Solutions) was used according to the manufac-
turer's protocol.
Soft agar assays
Cells were trypsinized, neutralized, and 1.2 × 104 cells
were plated per well in 0.36% bacto-agar (BD Bio-
sciences), w/v in growth media, on a 0.6% bacto-agar sup-
port in 6-well culture plates. Prior to cell plating, 250 ng/
mL doxycycline, DMSO vehicle, or the anti-EGFR com-
pound PD153035 (Calbiochem), was added to the agar,
as appropriate. Appropriately-supplememented fresh
media was added to wells every 4 days. Colonies greater
than 100 μm in diameter were counted after 18 days using
a 2× lens equipped with a graded grid to determine colony
size.
Alamar Blue growth assays in ultra-low attachment tissue 
culture plates
Cells were trypsinized and plated in 500 μL appropriate
growth media into 24-well ultra-low attachment plates
(Corning) at 25,000 cells per well. At the times indicated,
50 μL of alamar blue (BioSource International) was added
to each well and incubated for 6 hours under standard cul-
ture conditions. The amount of alamar blue reduction was
quantified by measuring the fluorescence of each sample
at 530 nm excitation/590 nm emission, corrected for the
background fluorescence in wells containing media but
no cells. The number of cells for initial plating and the
alamar blue incubation times were determined by gener-
ating a standard curve of fluorescence versus cell number
incubated with alamar blue for various times. Plating cells
initially at 25,000/well insures that fluorescence measure-
ments will occur on a linear part of the curve with a 6-
hour incubation time over the course of an experiment. It
was determined that TDAG51-specific shRNA did not
affect the redox potential of HME16C at various cell num-
bers. Statistical analysis was performed using 2-way anal-
ysis of variance (ANOVA) with Bonferroni post-tests using
the GraphPad Prism software program (GraphPad Soft-
ware, Inc.).
Tumorigenicity assays
Tumorigenicity assays were done essentially as described
[23]. To induce gene expression, cells were treated with
250 ng/mL doxycycline three days prior to injection, and
mice were fed with doxycycline-containing diet (200 mg/
kg, BioServ, Inc.) beginning four days prior to cell inocu-
lation and continuing for the duration of the experiment.
Microarray analysis
Total RNA was extracted using Trizol reagent (Invitrogen)
after treatment of cells with 250 ng/mL doxycycline for 72
hours to induce gene expression, or with doxycycline and
0.25  μM EGFR receptor kinase inhibitor PD153035 as
indicated. Twenty micrograms of RNA were used for
cDNA generation, and cDNA labeled with Cy3 or Cy5
monofunctional reactive dye to amino allyl-modified
dUTP incorporated into cDNA using the FairPlay Microar-
ray labeling kit (Stratagene). Labeled cDNA was hybrid-
ized to long-oligo (70-mer) cDNA microarrays from the
NCI/CCR Microarray Center, NCI, Frederick, MD, accord-
ing to standard protocols [25]. Hybridized arrays were
analyzed using a GenePix 4000B array scanner and Gene-
Pix Pro 4.0 software (Axon Instruments, Molecular
Devices Corporation). Data from GenePix Pro 4.0 was
uploaded to the microarray database at the NCI/CCR
Microarray Center website [25] for further analysis. Signal
intensities of microarray features were calculated by sub-BMC Cancer 2008, 8:189 http://www.biomedcentral.com/1471-2407/8/189
Page 4 of 16
(page number not for citation purposes)
tracting the median local background from the median
signal intensity. Features were considered for analysis if
the signal intensity was greater than one standard devia-
tion above background with at least a 2:1 signal-to-back-
ground ratio. Signal intensities for an entire microarray
were normalized to the 50% percentile median value.
After filtering and normalization, the Cy3 and Cy5 values
were expressed as a ratio to indicate the fold up- or down-
regulation. Two independent experiments for each com-
parison were performed, with a dye switch for each exper-
iment, therefore yielding four separate data sets. For
determining gene expression changes greater than or less
than 2-fold, data sets were filtered for genes containing at
least two significant values out of four array sets. Prior to
filtering, all data points were analyzed using statistical
analysis of microarray (SAM) data and a resultant gene set
was chosen at a delta value of 0.4 that limited the false dis-
covery rate (number of predicted false positive values/
number of significant genes) for each analysis to less than
1%. Minimal information about a microarray experiment
(MIAME)-compliant microarray data has been deposited
with the National Center for Biotechnology Information
(NCBI) Gene Expression Omnibus, accession number
GSE8916, available at [26].
Real-time RT-PCR analysis
cDNA was synthesized from RNA obtained for microarray
analysis using the SuperScript™ III First-Strand Synthesis
System for RT-PCR (Invitrogen). Quantification of relative
cDNA levels for each gene was accomplished using the
Platinum® SYBR® Green qPCR Supermix UDG real-time
RT-PCR kit (Invitrogen) and a Rotor-Gene3000™ thermo-
cycler with Rotor-Gene 5.0.37 software (Corbett
Research) that calculates relative PCR synthesis rates by
comparative quantification. The specificity of product
synthesis was verified by melting curve analysis by the
Rotor-Gene 5.0.37 software, and by running of real-time
PCR products on 2% agarose gels to verify product size
and rule out primer-dimer contribution to calculated val-
ues. The sequence-specific primers used in real-time RT-
PCR can be found in Additional file 2.
Cell cycle analysis
Cells grown under anchorage-independent conditions
were spun down, washed once in sterile PBS, and sus-
pended in a 50% mixture of PBS and ACCUMAX cell
detachment solution (Chemicon International) for 10
minutes at 25°C to dissociate cell clumps. After dissocia-
tion, cells were washed once in cold PBS and then fixed
with 70% ethanol. Fixed cells were treated with RNAse A
for 20 minutes at 37°C, and nuclear DNA was stained
with 50 μg/mL propidium iodide at 4°C. Cell cycle pro-
files were generated using a FACSCalibur flow cytometer
(BD Biosciences) and modeling cell cycle phases with the
cell cycle option of FlowJo flow cytometry software (Tree
Star, Inc.) after gating for viable, single cells. Statistical
analysis was performed using 2-way ANOVA with Bonfer-
roni post tests using the GraphPad Prism software pro-
gram (GraphPad Software, Inc.).
EdU cell proliferation assay
Measurement of cell proliferation by 5-ethynyl-2'-deoxyu-
ridine (EdU) incorporation was measured using the Click-
iT EdU cell proliferation Assay Kit for Flow Cytometry
(Invitrogen) according to the manufacturer's protocol.
Briefly, cells were plated at 1 × 106 cells per well in 6-well
ultra-low attachment plates or 5 × 105 cells per dish in 60
mm tissue culture dishes for attached control cells.
Attached cells were treated with either DMSO or 10 μM
EdU for 4 hours, and cells grown in low attachment plates
were treated with DMSO or 10 μM EdU for 24 hours.
Using FlowJo flow cytometry software (Tree Star, Inc.),
DMSO-treated control cells were used to determine the
threshold above which cells could be considered EdU pos-
itive, and the fraction of cells incorporating EdU was then
determined for experimental samples.
Cytotoxicity assay
The release of lactose dehydrogenase (LDH) into cell cul-
ture supernatant was measured using the cytotoxicity
detection kit LDH (Roche Molecular Biochemicals)
according to the manufacturer's instructions.
Results
Generation of H-Ras- and Rlf-CAAX-expressing HME16C 
cell lines
Retroviral vectors coding for amino terminal HA-tagged
activated H-RasV12, the H-RasV12 effector domain mutants
(EDM) H-RasV12G37, H-RasV12S35, and H-RasV12C40, and the
constitutively activated version of a RalGEF, Rlf-CAAX,
were used to infect telomerase immortalized HME16C
human mammary epithelial cells. Anti-Ras and anti-HA
western blotting demonstrated approximately equal levels
of ectopic Ras expression among Ras-infected cells, with
slightly lower levels in HME16C RasV12-infected cells rela-
tive to EDM-infected cells (Figure 1A). Analysis of acti-
vated, GTP-bound Ral A demonstrated highly elevated
levels of activated Ral A only in Rlf-CAAX-expressing cells
and not in Ras-infected cells grown under standard culture
conditions (Figure 1B). To assess activation of the ERK
pathway, anti-phospho Erk western blotting was per-
formed and showed significantly elevated Erk phospho-
protein in RasV12- and RasV12S35-infected HME16C cells
relative to control pLRT-infected cells (Figure 1A). Ele-
vated levels of phosphorylated Erk were also observed in
RasV12G37- and RasV12C40-infected cells, although at a
much lower level than that found in RasV12- and RasV12S35-
infected cells. To assess activation of the PI3K signaling
pathway, anti-phosphoAkt (Ser473) western blotting was
performed to detect activated, phosphorylated Akt. InBMC Cancer 2008, 8:189 http://www.biomedcentral.com/1471-2407/8/189
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cells that were serum starved for 24 hours and matrix
detached for 6 hours, elevated levels of phosphorylated
Akt were observed in RasV12-, RasV12C40-, and RasV12G37-
infected HME16C, with highest levels present in RasV12-
infected cells (Figure 1C).
Anchorage-independent growth of mammary epithelial 
cell lines
To assess transformation by different Ras signaling path-
ways, anchorage-independent growth assays were per-
formed in soft agar and in ultra-low attachment tissue
culture plates. Ras- and Ras EDM-infected HME16C cells
formed significantly more soft agar colonies >100 μm in
diameter than pLRT vector-infected cells (Figure 2A). The
RasV12-infected cells formed large colonies, many exceed-
ing 1000 μm, although the total number exceeding 100
μm was typically less than that for the Ras EDM (Figure
2B). Among the Ras EDM-infected cells, the RasV12S35-
infected cells formed the largest colonies. These were sim-
ilar to, but smaller than, the RasV12-infected cells. For col-
onies above 100 μm in diameter, RasV12C40-infected cells
were the most efficient at colony formation, despite the
smaller mean size of colonies. Rlf-CAAX-infected cells
formed slightly more colonies above 100 μm than vector-
transfected control cells, but these were significantly
smaller than those formed by Ras- and Ras EDM-infected
cells.
When grown under anchorage-independent conditions in
ultra-low attachment plates, the accumulation of cells for
the various infected cell lines roughly paralleled the total
cell masses seen in soft agar growth assays (Figure 2C).
The RasV12- and RasV12 EDM-expressing cells grew well,
while the growth of the Rlf-CAAX-expressing cells was sig-
nificantly less. The HME16C cells maintained viability but
did not increase in number.
Protein expression and pathway activation in HME16C cell lines Figure 1
Protein expression and pathway activation in HME16C cell lines. (A) Expression of HA-tagged H-RasV12, H-RasV12 
effector domain mutants, and Rlf-CAAX in HME16C mammary epithelial cells. In this and subsequent figures, cells infected with 
the following vectors are indicated as follows: pLRT control (pLRT), H-RasV12 (V12), H-RasV12G37 (G37), H-RasV12S35 (S35), H-
RasV12C40 (C40), and Rlf-CAAX (Rlf-CAAX). Cells were treated with 250 ng/mL doxycycline for 72 hours to induce gene 
expression, and anti-HA (HA tag) and anti-Ras (Ras) western blotting were performed. Erk activation was determined by west-
ern blotting for phosphorylated Erk (Phospho-Erk). The blot was subsequently stripped and probed with an anti-Erk2 antibody 
(Erk2). (B) Ral A activation was determined by a pull-down assay for GTP-bound, activated Ral A (GTP-Ral A). Total Ral A pro-
tein from lysates used in the Ral activation assay pull-down was determined by anti-Ral A western blotting (Ral A). (C) Akt acti-
vation in cell lysates was assessed by western blotting for phosphorylated Akt (Phospho-Akt). The membrane was stripped and 
probed with an anti-Akt antibody (Total Akt).BMC Cancer 2008, 8:189 http://www.biomedcentral.com/1471-2407/8/189
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To compare our results to others, we verified the function
of pLRT vector driven Ras EDM mutants and Rlf-CAAX in
HEK-HT cells, which previously have been reported to
form colonies in soft agar upon expression of H-RasV12G37
and Rlf-CAAX [27]. In our hands, expression of H-RasV12,
H-RasV12G37, and Rlf-CAAX from the pLRT vector induced
efficient soft agar colony growth, and H-RasV12S35 and H-
RasV12C40 did not (not shown), identical to previously
reported results [27]. Expression of exogenous H-Ras and
Rlf-CAAX, and activation of endogenous RalA, in this cell
line was similar to that observed in HME16C cells (not
shown). Therefore, expression of Rlf-CAAX and subse-
quent RalA activation did not appear to be sufficient to
induce anchorage-independent growth in the HME16C
mammary epithelial cell line in contrast to HEK-HT and
various other immortalized human cell types [27].
Tumorigenesis of HME16C cell lines in nude mice
Anchorage-independent growth often predicts the ability
of cells to grow as xenografted tumors in immuno-com-
promised mice. Tumor formation was assessed following
subcutaneous inoculation. The RasV12-infected HME16C
cells formed rapidly growing, fluid-filled tumors with an
average latency of 4 weeks and a mean tumor volume of
808.8 mm3 at 6 weeks (Table 1). Approximately one-half
of the tumors were aspirated prior to sacrifice, and a sero-
sanguinous fluid was observed, on average accounting for
roughly one-third of the measured tumor volume. Histo-
logical analysis of H&E stained tumor sections revealed
poorly differentiated spindle-shaped tumor cells with
prominent squamous cell differentiation and extracellular
keratin deposition (not shown). Tumors also contained a
strong inflammatory component. Of the other cell lines
tested, only the RasV12S35-infected HME16C cells formed
Anchorage-independent growth of HME16C cell lines Figure 2
Anchorage-independent growth of HME16C cell lines. (A) Number of soft agar colonies exceeding 100 μM after 21 
days of growth for HME16C cell lines infected with pLRT control, H-RasV12, H-RasV12G37, H-RasV12S35, H-RasV12C40, and Rlf-
CAAX-expressing constructs. (B) Representative pictures of colony sizes in soft agar assays. Bar represents 200 μm. (C) 
Anchorage-independent growth of cell lines grown on ultra-low attachment plates treated with DMSO vehicle (left) or 0.25 
μM PD153035 (right) measured using the alamar blue assay. RFU, relative fluorescence units of alamar blue product formed.BMC Cancer 2008, 8:189 http://www.biomedcentral.com/1471-2407/8/189
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palpable tumors in 50% of injected animals with an aver-
age latency of approximately 12 weeks and a mean tumor
volume of 109.0 mm3 at 16 weeks, considerably smaller
than RasV12-expressing tumors (Table 1). Cells within
RasV12S35-infected tumors resembled the histology of
RasV12 tumor cells but with less keratin deposition and
without the formation of fluid-filled spaces (not shown).
Empty vector-, RasV12G37-, RasV12C40-, and Rlf-CAAX-
infected cells failed to form palpable tumors four months
after injection. The metastatic potential of RasV12- and
RasV12G37-expressing cell lines was tested by tail-vein injec-
tion in nude mice, but no metastatic lesions were
observed by histological analysis in lungs, liver, spleen, or
kidneys at 16 weeks post injection (not shown).
Autocrine EGFR signaling is required for RasV12G37- and 
RasV12C40-mediated, but not RasV12S35-mediated, HME16C 
cell anchorage- independent growth
EGFR signaling is frequently altered in breast cancer,
where EGFR and ErbB2 over-expression are common
events. cDNA microarray and real-time RT-PCR analysis
of HME16C RasV12- and Ras EDM-infected cells (Addi-
tional file 1) revealed increased levels of mRNAs for EGFR
ligands, including epiregulin, amphiregulin, and TGFa
(Table 2). In addition, increased levels of phospho-Erk
were unexpectedly seen in RasV12G37- and RasV12C40-
infected cells, possibly the result of autocrine activation of
endogenous EGFR by secreted EGFR ligands. The presence
of EGFR was established using Western blots (not shown).
Therefore, we sought to determine if autocrine signaling
by the EGFR was required for the anchorage-independent
growth of Ras- or Ras EDM-infected cells. RasV12- and Ras
EDM-infected HME16C cells were grown in soft agar in
the presence or absence of the EGFR-specific inhibitors,
PD153035 and PD168393. Complete inhibition of col-
ony formation for RasV12G37-infected and RasV12C40-
infected cells was observed at 0.25 μM PD153035, a con-
centration that specifically inhibits EGFR [28], whereas
both the RasV12- and RasV12S35-infected cells formed colo-
nies efficiently at this same concentration of inhibitor
(Figure 3A and 3B). Identical results were found for the
EGFR-specific inhibitor PD168393 used at 0.1 μM, a con-
centration that specifically inhibits EGFR and Her-2 recep-
tors [29](not shown). Similarly, treatment of cells grown
in ultra-low-attachment plates also demonstrated that
EGFR inhibition substantially inhibited growth of
RasV12G37-and RasV12C40-expressing cells relative to that of
RasV12- and RasV12S35-expressing HME16C (Figure 2C).
Western blotting of cellular lysates from cells treated with
0.25 μM PD153035 showed that high levels of phospho-
rylated Erk were maintained only in RasV12- and RasV12S35-
infected cells, but were significantly reduced in RasV12G37-
or RasV12C40-infected cells treated with the inhibitor (Fig-
ure 3C), while phoshorylated Akt was minimally affected
(not shown). Anchorage-independent growth therefore
correlated with maintenance of high Erk activity in
HME16C cells. Consistent with this observation, inhibi-
tion of MEK, and therefore ERK signaling, using the MEK-
specific inhibitor PD98059 at 10 μM, significantly inhib-
ited soft agar colony formation by all cell lines (not
shown).
Microarray analysis of gene expression changes in RasV12-, 
RasV12G37-, RasV12S35-, and RasV12C40-infected HME16C 
cells
Activation of the Ras oncogene is accompanied by the
stimulation of multiple signal transduction pathways
leading to the activation or repression of numerous tran-
scription factors as well as changes in mRNA translation
and stability, and thus, the modulation of gene expres-
sion. To determine which gene expression changes accom-
pany the transformation of HME16C human epithelial
cells by activated Ras, we examined our transformed
Table 1: Growth of HME16C tumors in nude mice
Cell Line Innoculated Number of Mice with Tumors Mean Tumor Latency Mean Tumor Volume at Sacrifice (mm3)*
pLRT 0/10 - -
H-RasV12 10/10 4 weeks 808.8 +/- 635.2
H-RasV12G37 0/10 - -
H-RasV12S35 5/10 12 weeks 109.0 +/- 171.0
H-RasV12C40 0/10 - -
Rlf-CAAX 0/10 - -
Cells infected with control, Ras-expressing, or Rlf-CAAX-expressing retrovirus were injected subcutaneously into nude mice and examined for 
tumor formation and growth. *For mice injected with H-RasV12S35 cells, includes only sites that formed tumors.
Table 2: Up-regulation of EGFR ligands in RasV12- and Ras EDM-
expressing HME16C
Gene V12 S35 G37 C40
epiregulin 2.6 (7.0) 1.9 (1.0) 1.8 (2.4) 1.2 (1.3)
TGFa 3.5 (3.4) 2.9 (1.3) -1.1 (-1.4) 1.9 (-1.1)
amphiregulin 1.4 (2.4) 2.9 (1.0) 2.3 (1.7) 2.2 (1.0)
Fold up-regulation of the EGFR ligands epiregulin, transforming 
growth factor alpha (TGFa), and epiregulin in RasV12- and Ras EDM-
expressing HME16C as determined by real-time RT-PCR 
quantification (boldface) and cDNA microarray analysis (in 
parentheses).BMC Cancer 2008, 8:189 http://www.biomedcentral.com/1471-2407/8/189
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HME16C cells by cDNA microarray analysis. To do this,
RNA was isolated from H-RasV12  and H-RasV12  EDM
expressing cells after treatment with doxycycline to fully
induce gene expression and compared to RNA from iden-
tically treated pLRT vector-infected control cells. Statistical
analysis of microarray (SAM) data analysis was performed
for the datasets, and a delta value of 0.4 was chosen for
each dataset, which maintains the estimated false discov-
ery rate (FDR) below 1% for each. A summary of the genes
up- or down-regulated greater than 2-fold in the H-RasV12-
and Ras effector domain mutant-infected HME16C cell
lines is presented in Additional file 1, organized according
to broad categories of gene function. To validate gene
expression changes identified by cDNA microarray analy-
sis, quantitative RT-PCR was performed using RNA from
the same samples used in microarray analysis, and is pre-
sented in Additional file 2. Results for 22 of 26 genes cho-
sen to reflect genes up- or down-regulated both strongly or
weakly showed strong agreement with microarray data,
demonstrating that the microarray dataset represents a
reliable quantification of gene expression changes.
To evaluate the effect of EGFR inhibition on gene expres-
sion, RasV12-, RasV12S35-, and RasV12G37-infected cells were
induced with doxycycline and subsequently incubated
either in the presence or absence of 0.25 μM PD153035,
and microarray analysis comparisons were made to vehi-
cle-treated pLRT-infected cells. Almost all Ras and Ras
EDM-induced upregulated transcriptional responses were
blocked by pharmacological inhibition of EGFR, consist-
ent with previous reports for inhibition of Raf-regulated
transcription [30]. Our analysis identified PHLDA1 as an
up-regulated gene in both vehicle-treated and PD153035-
treated RasV12 and RasV12S35 cells, although the relative
fold increase was reduced following EGFR inhibition. By
comparison, PHLDA1 was down-regulated in PD153035-
treated RasV12G37  relative to vehicle-treated cells (not
shown). Therefore, PHLDA1 represents a Raf/ERK-respon-
Anchorage-independent growth of HME16C cell lines after EGFR inhibition Figure 3
Anchorage-independent growth of HME16C cell lines after EGFR inhibition. (A) Cell lines, as indicated, were grown 
in the soft agar assay for 21 days either in the presence of DMSO vehicle or 0.25 μM PD153035 EGFR inhibitor. Scale bar, 200 
μm. (B) Number of colonies >100 μm in size for each cell line treated with either DMSO vehicle or 0.25 μM of the EGFR-spe-
cific inhibitor PD153035. Statistical analysis was performed using one-way analysis of variance with Bonferroni post-test analy-
sis. NS, not significant, p > 0.05; *, p < 0.0001. (C) Activation of Erk after EGFR inhibition. Cell lines were grown in the 
presence of DMSO vehicle or 0.25 μM PD153035 for 48 hours, followed by western blotting for phosphorylated Erk (Phos-
pho-Erk). The blot was stripped and probed with an anti-Erk 2 antibody (Erk 2) to verify equal protein loading. The phospho-
ERK blot was overexposed in order to reveal minimal levels of protein.BMC Cancer 2008, 8:189 http://www.biomedcentral.com/1471-2407/8/189
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sive gene whose expression parallels EGFR-independent
HME16C mammary epithelial cell transformation.
TDAG51 expression is up-regulated by Ras signaling in a 
ERK-dependent manner, and is associated with EGFR-
independent transformation
The PHLDA1 gene is of interest as it has been suggested to
be a tumor suppressor in breast adenocarcinoma and
melanoma [17,18]. We further analyzed the signal
dependent expression of the PHLDA1 gene and its protein
product, TDAG51. Microarray analysis identified the
PHLDA1 gene as being dramatically up-regulated in
RasV12- and Ras EDM-infected cells to levels that corre-
lated with the level of ERK activation and the extent of
anchorage-independent growth (Additional file 1). West-
ern blotting confirmed that TDAG51 was also upregulated
in a similar manner (Figure 4A). The PHLDA1 gene was
elevated in PD153035-treated RasV12- and RasV12S35-
infected cells but was significantly dependent upon EGFR
tyrosine kinase activity for upregulation in RasV12G37- and
RasV12C40-infected cells (not shown), and the expression
of the encoded TDAG51 protein approximately paralleled
PHLDA1 RNA expression (Figure 4B). As shown in Figure
3C, EGFR inhibition significantly reduced ERK signaling
in RasV12G37- and RasV12C40-infected cells without affecting
RasV12- and RasV12S35-infected cells. To confirm that
TDAG51 up-regulation was induced specifically by ERK
activation, we treated pLRT-, RasV12-, and RasV12S35-
infected cells with the MEK-specific inhibitor PD98059.
PD98059 used at 20 μM appears to be specific for MEK1
as it does not nonspecifically inhibit a variety of other pro-
tein kinases that have been assayed. [31]. TDAG51 up-reg-
ulation was attenuated by MEK inhibition (Figure 5).
TDAG51 therefore represents an ERK-inducible gene
whose up-regulation in HME16C is correlated with an
EGFR-independent, ERK-mediated transformation.
TDAG51 up-regulation opposes ERK-mediated HME16C 
transformation
To analyze the role of TDAG51 in ERK-dependent growth,
we reduced TDAG51 expression in RasV12- and RasV12S35-
infected cells to a level comparable to that in non-trans-
formed vector-infected control cells using stably expressed
TDAG51-specific shRNA (Figure 6A). Cell proliferation of
attached cells grown on tissue culture plastic was unaf-
fected by lowered TDAG51 protein levels (not shown).
However, cell growth under anchorage-independent con-
ditions in ultra-low attachment plates was significantly
enhanced by TDAG51 knock-down in RasV12S35-infected
cells (Figure 6B). Likewise, results with RasV12-infected
cells stably infected with TDAG51-targeting shRNA also
showed enhanced growth relative to vector-infected con-
trol cells, although to a lesser extent than that seen with
RasV12S35-infected cells (Figure 6C). This suggests that Ras
signaling pathways other than ERK compensate partially
for the negative growth effects of TDAG51, or that RasV12-
infected cells are already close to maximally transformed
under anchorage-independent growth conditions.
Loss of TDAG51 expression in transformed cells stimulates 
both cell cycle progression and apoptosis
To characterize the effect of TDAG51 on cell proliferation
under anchorage-independent conditions, cell cycle anal-
ysis and cell proliferation assays for RasV12S35- and RasV12-
infected cells were performed. Both RasV12S35- and RasV12-
TDAG51 shRNA-expressing cells demonstrated an
increased S-phase fraction versus pLVTHM vector control
cells at various time points during anchorage-independ-
ent growth (Figure 7A). In concordance with these results,
RasV12S35 and RasV12 cells expressing the TDAG51-specific
shRNA showed enhanced incorporation of 5-ethynyl-2'-
deoxyuridine (EdU) in cell proliferation assays, indicating
a higher rate of DNA synthesis in cells with reduced
TDAG51 protein (Figure 7C).
Since cell growth under anchorage-independent condi-
tions is a balance between cell proliferation and cell
death, we sought to evaluate the effect upon cellular death
of TDAG51 knock-down. We used an assay of cellular
cytotoxicity that measures the release of the lactose dey-
drogenase enzyme, LDH. LDH release was increased by
TDAG51 shRNA-expressing RasV12S35  cells relative to
pLVTHM-infected cells at various time points after the ini-
tiation of matrix-detached growth (Figure 8). The differ-
ence in LDH release for TDAG51 shRNA-expressing RasV12
cells was minimal and rarely approached statistical signif-
icance. Sub-G1 peaks indicative of dead cells were some-
times seen with cell cycle analysis at late time points, but
varied from experiment to experiment. Therefore, for
RasV12S35-infected cells, the differences in cell growth after
TDAG51 reduction under anchorage-independent condi-
tions resulted from an enhanced rate of cellular prolifera-
tion that exceeded a concomitant increase in cell death.
Reduction of TDAG51 in transformed cells enhances 
proximal ERK signaling
Reducing TDAG51 protein levels in ERK-driven cellular
transformation enhanced cell growth under anchorage-
independent, but not attached, conditions. To test
whether TDAG51 might affect proximal ERK signaling, we
examined the activation status of Erk in cells expressing
TDAG51-specific shRNA. Interestingly, the levels of phos-
phorylated Erk were enhanced when TDAG51 protein lev-
els were reduced in RasV12S35 and RasV12 cells grown under
anchorage-independent, but not attached, conditions
(Figure 9). The fact that the activation status of Erk was
unchanged in cells grown under attached conditions sug-
gests that reducing TDAG51 expression had no selective
effect with regard to ERK activation in these cells. Rather,BMC Cancer 2008, 8:189 http://www.biomedcentral.com/1471-2407/8/189
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Expression of TDAG51 in HME16C cell lines in the absence or presence of the EGFR inibition Figure 4
Expression of TDAG51 in HME16C cell lines in the absence or presence of the EGFR inibition. Western blotting 
of TDAG51 in HME16C cell lines. (A) Twenty-five micrograms of protein from HME16C cellular lysates were resolved by SDS-
PAGE and probed with an anti-TDAG51 monoclonal antibody (TDAG51). Equal protein loading was verified by stripping the 
blot and probing with an alpha tubulin monoclonal antibody (Alpha tubulin). Band intensities were determined using Image J 
software (NIH, Bethesda, MD) and TDAG51 values were normalized using alpha tubulin values. Fold expression of each band 
relative to HME16C parental: HME16C parental, 1.0; pLRT, 1.0; V12, 3.0; G37, 2.3; S35, 2.4; C40, 1.3; Rlf-CAAX, 0.9. Similar 
experiments to that shown were performed 2 additional times with similar results. (B) HME16C cell lines were treated with 
DMSO vehicle or 0.25 μM PD153035 EGFR-specific inhibitor for 48 hours, and cell lysates were prepared. Twenty five micro-
grams of protein were resolved by SDS-PAGE and western blotted with anti-TDAG51 mAb (TDAG51). The blot was subse-
quently stripped and probed with an alpha tubulin mAb (Alpha tubulin). Band intensities were determined using Image J 
software (NIH, Bethesda, MD) and TDAG51 values were normalized using alpha tubulin values. DMSO-treated cells are indi-
cated by a -, and PD1535035-treated cells are indicated by a +. Fold expression relative to DMSO-treated pLRT: pLRT -(1.0), 
+(0.2); V12 -(2.3), +(2.6); G37 -(0.8), +(0.3); S35 -(1.4), +(0.9); C40 -(1.1), +(0.6); Rlf-CAAX -(1.6), +(1.0). Similar experiments 
to that shown were performed 2 additional times with similar results.BMC Cancer 2008, 8:189 http://www.biomedcentral.com/1471-2407/8/189
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the enhanced activation of Erk was specific to anchorage-
independent growth conditions.
Discussion
Ras is a common signaling node for various cell surface
receptors that contribute to epithelial cell transformation
[14]. In this study, we used the hTERT-immortalized
human mammary epithelial cell line HME16C to examine
which Ras signaling pathways are sufficient for transfor-
mation and to identify transcriptional targets downstream
of those pathways that might modulate this phenotype.
Transduction of HME16C with pathway-discriminating
Ras effector domain mutants demonstrated that multiple
downstream Ras signal transduction pathways contribute
to anchorage-independent growth including Raf-, Ral-
GEF-, and PI3K-mediated signaling. Transformation of
HME16C by the RasV12G37 effector domain mutant but not
activated Rlf-CAAX suggest that RasV12G37-binding effec-
tors other than RalGEF contribute to mammary epithelial
transformation.
Microarray analyses of RasV12 and Ras effector domain
mutant transduced cells demonstrated a common upreg-
ulation of EGFR ligands among transformed cell lines.
This suggested that autocrine EGFR ligand secretion was
an important component of Ras-mediated cellular trans-
formation. Following blockade of EGFR signaling with
the EGFR-specific inhibitor PD153035, the only pathway
downstream of Ras that promoted anchorage-independ-
ent growth was Raf/ERK, suggesting that Raf activation
was able to substitute for EGFR activity in this cell line. In
contrast, previous studies with MCF10A cells demon-
strated that EGFR tyrosine kinase activity was necessary to
inhibit anoikis upon matrix detachment, even in cells
expressing activated Raf [16]. By contrast, under matrix
detached conditions, the parental HME16C cells are non-
proliferative, but do not actively undergo anoikis. The
studies here measure a proliferative response of Raf/ERK
activation in the absence of a strong apoptotic compo-
nent. In addition, blockade of MEK activity with the MEK-
specific inhibitor PD98059 prevented the transformation
of RasV12- and RasV12S35-expressing cells. This, taken
together with the finding that RasV12- and RasV12S35-trans-
duced HME16C cells were able to form tumors in nude
mice, indicates that the Raf-MEK-Erk axis plays a crucial
role in mediating transformation and tumorigenesis in
this model. However, it should be noted that Ras-trans-
formed HME16C, as well as the similar HMLER [32], give
rise to squamous metaplasias and not adenocarcinomas.
It has been hypothesized that HMLE human mammary
epithelial cells represent a distinct precursor population
from those mammary epithelial cells that give rise to glan-
dular adenocarcinomas, the predominant form of breast
cancer [32].
The significantly reduced tumorigenicity of RasV12S35- as
compared to RasV12- expressing cells emphasizes the
importance of cooperation between Ras signal transduc-
tion pathways for a fully transformed phenotype. Follow-
ing EGFR inhibition, RasV12C40- and RasV12G37- transduced
lines lost anchorage-independent growth, suggesting that
non-ERK signaling pathways contribute to cellular trans-
formation through an EGFR dependent mechanism.
Indeed, one consequence of EGFR activation is ERK path-
way activation and may explain the role of EGFR in coop-
erating with RasV12G37- and RasV12C40-mediated cell
signaling to promote anchorage-independent growth.
Microarray analyses identified up-regulation of the
PHLDA1 gene product as being correlated with ERK-
mediated cellular transformation. Likewise, the protein
product of the PHLDA1 gene, TDAG51, displayed an
identical expression pattern. Expression of PHLDA1
mRNA and TDAG51 protein in breast cancer has recently
been described [17]. Using TDAG51 immunohistochem-
istry of tissue microarrays, 699 individual primary inva-
sive breast tumor specimens were examined; loss of
TDAG51 was found to correlate with a poorer disease-free
and overall survival rate in multivariate analysis. Similar
results have been found in a small series of melanomas,
where TDAG51 immunoreactivity was found to decrease
during the progression of melanocytic nevi to primary
melanomas and finally to metastatic melanoma [18].
These studies suggest that TDAG51 has a suppressive
TDAG51 expression is induced by ERK pathway activation Figure 5
TDAG51 expression is induced by ERK pathway acti-
vation. HME16C cell lines infected with pLRT empty vector 
(pLRT), RasV12 (V12), or RasV12S35 (S35) were treated with 
0.2% DMSO vehicle or 20 μM PD98059 for 24 hours, fol-
lowed by western blotting for TDAG51. The blot was 
stripped and probed with an alpha tubulin monoclonal anti-
body (Alpha tubulin) to demonstrate equal protein loading. 
Band intensities were determined using Image J software 
(NIH, Bethesda, MD) and TDAG51 values were normalized 
using alpha tubulin values. Fold expression of PD98059-
treated relative to DMSO-treated contols: pLRT (0.6); V12 
(0.6); S35 (0.3). Similar experiments to that shown was per-
formed 1 additional time with similar results.
pLRT S35
- + - + 20μM PD98059
TDAG51
Alpha tubulin
V12
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effect on tumor progression and prompted us to evaluate
the cell biological function of TDAG51 in the HME16C
transformation model.
The PHLDA1 gene is a member of the pleckstrin homol-
ogy-related domain family that includes Ipl/Tssc and Tih
[33]. PHDLA1 has been described as an immediate early
gene with transcriptional activation resulting from
engagement of receptors such as the FGF and IGF tyrosine
kinase receptors and the T-cell receptor [34-36]. Strong
TDAG51 induction by RasV12S35 transformation of mam-
mary epithelial cells suggests that ERK activation may at
least partially explain TDAG induction in these previous
reports. In vitro studies have suggested a role for TDAG51
in the control of cellular proliferation and in the induc-
tion of apoptosis in response to a variety of stresses
including proteotoxic cellular stresses such as lung cancer
cell responses to chemotherapy[35,37-39].
Overexpression of TDAG51 has been shown to reduce cell
proliferation and induce cell death in a variety of cell types
including T cells, neuronal, endothelial, melanoma, and
cervical carcinoma cell types [34,35,38]. By contrast,
TDAG51 functioned as an anti-apoptotic factor down-
stream of insulin-like growth factor receptor (IGFR) sign-
aling as TDAG51 was required to protect NIH3T3 cells
from apoptosis upon IGF-1 withdrawal [36].
Reduction of TDAG51 levels in RasV12 and RasV12S35 cells
enhanced cell proliferation under anchorage-independent
conditions. This suggests that TDAG51 expression limits
cellular proliferation. In addition to enhancing cellular
proliferation, reduction of TDAG51 protein levels also
increased the absolute amount of cell death in trans-
formed RasV12S35  cells under these same conditions.
Therefore, TDAG51 loss, in the context of oncogene acti-
vation, may indirectly promote cell death as a conse-
quence of enhanced cell cycling. However, the overall
increased cell numbers in anchorage-independent condi-
tions showed that enhanced cellular proliferation
exceeded enhanced cell death.
Interestingly, a decrease in TDAG51 expression during
Ras-mediated cellular transformation promoted the
Reduction of TDAG51 expression in RasV12 and RasV12S35-infected cells and their anchorage-independent growth Figure 6
Reduction of TDAG51 expression in RasV12 and RasV12S35-infected cells and their anchorage-independent 
growth. (A) Western blotting of TDAG51 protein (TDAG51) from 5 μg of cellular lysates from non-silencing vector control 
(pLVTHM) and anti-TDAG51 shRNA (36-1) -expressing cell lines as indicated. The blot was subsequently stripped and probed 
with an anti-alpha tubulin mAb (Alpha tubulin). Band intensities were determined using Image J software (NIH, Bethesda, MD) 
and TDAG51 values were normalized using alpha tubulin values. Fold expression of each band relative to HME16C pLRT 
pLVTHM: pLRT pLVTHM (1.0), 36-1 (0.4); V12 pLVTHM (2.3), 36-1 (1.0); S35 pLVTHM (1.5), 36-1 (0.7). Similar experiments 
to that shown were performed 2 additional times with similar results (B) Growth of pLVTHM vector control or TDAG51 
shRNA-expressing RasV12S35-transduced cells either in the presence of 0.2% DMSO control (left) or 0.25 μM PD153035 (right) 
in low-attachment plates, assessed by the alamar blue growth assay. RFU, relative fluorescence units. (C) Growth of pLVTHM 
vector control or TDAG51 shRNA-expressing RasV12-transduced cells either in the presence of 0.2% DMSO control (left) or 
0.25 μM PD153035 (right) in ultra-low-attachment plates, assessed by the alamar blue growth assay. RFU, relative fluorescence 
units.
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growth of cells under anchorage-independent conditions
but did not affect the growth of attached cells. This sug-
gests that TDAG51 might act in conjunction with both cel-
lular stress, in this case matrix detachment, and a
proliferative signal, in this case oncogenic activation.
Other studies also have implicated TDAG51 in function-
ing during cellular stress and survival, particularly endo-
plasmic reticulum stress associated with the unfolded
protein response [37,38]. A mechanism of action for
TDAG51 is not known. The preliminary finding that
TDAG51 binds to proteins involved in protein translation
has been used to suggest that TDAG51 may play a role in
regulating protein synthesis in response to proteotoxic
stress [40].
Reduction of TDAG51 expression resulted in an increase
in Erk activation in cells grown under anchorage-inde-
pendent conditions. How TDAG51 expression might sup-
press ERK signaling is not known, but appears to represent
a negative feedback pathway that directly or indirectly
limits ERK activation. This is not likely to be due to an
inhibition of ERK protein synthesis by TDAG51, since
Erk2 levels were unaffected by reduced TDAG51. How-
ever, another important component of ERK activation is
the dual specific ERK phosphatases, a highly regulated
Cell proliferation is increased in Ras-transformed cell lines with reduced TDAG51 expression Figure 7
Cell proliferation is increased in Ras-transformed cell lines with reduced TDAG51 expression. (A) S phase frac-
tion of RasV12S35-expressing (left panel) or RasV12-expressing (right panel) HME16C infected with pLVTHM non-silencing vector 
control or anti-TDAG51 shRNA 36-1 after 48, 72, 96 or 120 hours growth in ultra-low attachment plates as determined by 
cell cycle analysis of propidium iodide-stained nuclei. * p < 0.05; **p < 0.01; ***p < 0.001. (B) Incorporation of the nucleoside 
analogue EdU into cellular DNA measured in RasV12S35-expressing (left panel) or RasV12-expressing (right panel) HME16C 
infected with pLVTHM non-silencing vector control or anti-TDAG51 shRNA 36-1 after 48, 72, 96 or 120 hours growth in 
ultra-low attachment plates. Incorporated EdU was quantified by detection of Alexa Fluor 488-labeled EdU in viable single cells 
by flow cytometry analysis.
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class of proteins, whose relative level of activity may be
affected by TDAG51 protein levels. Understanding the
mechanisms by which TDAG51 regulates ERK pathway
activation and the balance between cellular proliferation
and apoptosis of transformed cells represents a future
challenge. Finally, TDAG51 acts in a suppressive manner
during matrix-detached growth of HME16C cells. Taken
together with the identification of TDAG51 as a stress-
induced gene in a variety of cell lines and a growth inhib-
itor in melanoma cell lines, it is reasonable to suggest that
loss of TDAG51 may act to promote progression of breast
cancer through an intrinsic growth regulatory mechanism.
Conclusion
Expression of activated Ras effector domain mutants that
bind Raf, PI3K, or RalGEF are sufficient to induce the
anchorage-independent growth of the human mammary
epithelial cell line HME16C and are associated with up-
regulation of EGFR ligands. However, only the ERK path-
way is capable of supporting transformation in the
absence of EGFR signaling and of supporting tumorigene-
sis in nude mice. Up-regulation of TDAG51 occurs during
Ras-mediated transformation in an ERK-dependent fash-
ion, but opposes ERK-mediated transformation by sup-
pressing ERK signaling and decreasing cellular
proliferation under matrix-detached conditions. There-
fore, in this model of mammary epithelial cell transfor-
mation, TDAG51 acts as a growth inhibitor of ERK-driven
proliferation and may help explain why loss of TDAG51
expression has been found to correlate with progression
in human breast cancer and melanoma.
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LDH release by RasV12S35- or RasV12-expressing HME16C infected with pLVTHM vector or anti-TDAG51 shRNA 36-1 Figure 8
LDH release by RasV12S35- or RasV12-expressing HME16C infected with pLVTHM vector or anti-TDAG51 
shRNA 36-1. (A) Relative LDH activity released by pLVTHM- or anti-TDAG51 shRNA 36-1-infected RasV12S35 cells was meas-
ured in the culture media of cells grown under anchorage-independent conditions in ultra-low attachment plates for the times 
indicated. * p < 0.05; **p < 0.01; ***p < 0.001. (B) Relative LDH activity released by pLVTHM- or anti-TDAG51 shRNA 36-1-
infected RasV12 cells. * p < 0.05.
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ERK pathway activation in RasV12 and RasV12S35 cells infected  with pLVTHM or anti-TDAG51 shRNA 36-1 Figure 9
ERK pathway activation in RasV12 and RasV12S35 cells 
infected with pLVTHM or anti-TDAG51 shRNA 36-1. 
RasV12 or RasV12S35 cells infected with either pLVTHM vector 
control or anti-TDAG51 shRNA 36-1 were grown for 72 
hours attached to tissue culture plastic (attached) or in ultra-
low attachment plates (anchorage-independent) in the pres-
ence of 250 ng/mL doxycycline. ERK pathway activation was 
measured by determination of phosphorylated Erk1/2 levels 
by western blotting using an anti-phosphorylated Erk mAb 
(phospho-Erk). The blot was stripped and subsequently 
probed with an anti-Erk2 mAb (Erk2).
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factor; Rlf: RalGEF-like factor; shRNA: small hairpin ribo-
nucleic acid; TDAG51: T-cell death associated gene of 51
kDa.
Competing interests
The authors declare that they have no competing interests.
The final text was reviewed and approved by all the listed
co-authors. They all contributed to the intellectual con-
tent and to the experimental work in an honest manner.
The contents have not been published by or submitted to
any other journal. No part of this text has been included
in any other paper.
Authors' contributions
Conception and design: MDO and KK. Provision of study
materials: MDO, JJY, YW, and KK. Collection and assem-
bly of data: MDO, SJB, and LZ. Data analysis and interpre-
tation: MDO and KK. Manuscript writing: MDO and KK.
Final approval of manuscript: MDO, SJB, LZ, JJY, YW, and
KK.
Additional material
Acknowledgements
This research was supported by the Intramural Research Program of the 
NIH, National Cancer Institute, Center for Cancer Research.
References
1. van 't Veer LJ, Dai H, Vijver MJ van de, He YD, Hart AA, Mao M,
Peterse HL, Kooy K van der, Marton MJ, Witteveen AT, et al.: Gene
Additional file 1
Selected microarray data for HME16C cell lines. The fold up-regulation 
or down-regulation of genes identified in microarray analysis is indicated 
for genes where this value exceeded two-fold, organized into categories 
according to broadly defined gene functions. PHLDA1 is categorized as an 
up-regulated gene under "Miscellaneous."
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-8-189-S1.doc]
Additional file 2
Real-time RT-PCR confirmation of selected microarray data. Results 
are for transcripts identified as up- or down-regulated in microarray anal-
ysis of cDNA from RasV12-, RasV12G37-, RasV12S35-, RasV12C40-, and Rlf-
CAAX-infected HME16C. Numbers represent fold expression changes for 
transcript levels relative to vector-infected pLRT control cells. Parentheti-
cal numbers indicate mean fold expression changes from cDNA microar-
ray analysis (see Additional file above). Sequences of primers used for 
real-time RT-PCR analysis are as follows: amphiregulin Forward 5'-
CGCCGGTGGTGCTGTCGCTCTT-3' Reverse 5'-TCACTCACAG-
GGGAAATCTCACTC-3', anterior gradient 2 Forward 5'-GGGGTGAC-
CAACTCATCTGGACTCAG-3' Reverse 5'-
GACATACTGGCCATCAGGAGAAAGGTGT-3', CD24 Forward 5'-
GCTCCTACCCACGCAGATTTATT-3' Reverse 5'-CACGAAGAGACT-
GGCTGTTGACT-3', c-met Forward 5'-AAATGGCCACG-
GGACAACACAA-3' Reverse 5'-TGGGCTGGGGTATAACATTCAAGA-
3', CTGF Forward 5'-CTGCCCGGGAAATGCTGCGAGGAGT-3' 
Reverse 5'-CTGCAGGAGGCGTTGTCATTGGTAA-3', CYR61 Forward 
5'-CGGCCCAAGTACTGCGGTTCCT-3' Reverse 5'-ATTGGCATGCG-
GGCAGTTGTAGTT-3', Decorin Forward 5'-ACTTCTGCCCACCT-
GGACACAACA-3' Reverse 5'-ATGGCAGAGCGCACGTAGACACA-3', 
DICER-1 Forward 5'-CAGGAAATACCCGTGCAACCAACTA-3' 
Reverse 5'-GCATTACGGCCATCACAGGACTTC-3', E-cadherin For-
ward 5'-GGTATCTTCCCCGCCCTGCCAATCC-3' Reverse 5'-AAC-
CGCTTCCTTCATAGTCAAACACGAG-3', EphA2 Forward 5'-
CCCCTTCCGCCCCACACTACCTCACAGC-3' Reverse 5'-ACACG-
GCCCGCATTCCCCAGACTCG-3', Epiregulin Forward 5'-TTG-
TATTTTTAGTAGAGGCGGGGTTTCA-3' Reverse 5'-
TCGGGCACAGATGTTCAAGTCAC-3', ETS-1 Forward 5'-ACTCG-
GGGGCCAGGACTCTTTTGAA-3' Reverse 5'-CACGGTCCCGCACAT-
AGTCCTTGAA-3', ETS variant gene 5 Forward 5'-
TCGGGGACGTCTACGGTTTCTACT-3' Reverse 5'-AAGACTG-
TAAACGGCTACCATTGA-3', FAT-2 Forward 5'-GCTGGACAT-
CAAACGGGCTAACAT-3' Reverse 5'-
ACCGCATCTGAACCCCCACTGAAT-3', HMGA-1 Forward 5'-GCT-
CACCCTGCCCGCTCCCAACC-3' Reverse 5'-GCCCCAGCCCCTCT-
TCCCCACAAA-3', HMGA-2 Forward 5'-
CTGATAAGCAAGAGTGGGCGGGTGAGAA-3' Reverse 5'-ACAG-
GGAGTGGGTTGGGGTGGTATTTGA-3', Secreted frizzled-related pro-
tein 1 Forward 5'-CCCGCTCCCTTTCCCTCCATA-3' Reverse 5'-
GCTCTCACTTTCCGCCCAATCC-3', Tenascin C Forward 5'-GCG-
GCCCAGAGCGAGGAA-3' Reverse 5'-TATTGCGATGTTGTCACT-
GGGAGATTTT-3', TGF-a Forward 5'-CCGCCTTGGTGGTGGTCTCC-
3' Reverse 5'-AGGGCGCTGGGCTTCTCGTG-3', TGF-β2 Forward 5'-
CCCGCCCACTTTCTACAGACCCTACT-3' Reverse 5'-CATTCGCCT-
TCTGCTCTTGTTTTCAC-3', TGF-β receptor 2 Forward 5'-ACAGT-
GGCAGTCAAGATCTTTCCCTATG-3' Reverse 5'-
CAACTCCGTCTTCCGCTCCTCAG-3', TRIM29 Forward 5'-ATGCAT-
GCGCCACGTTGAGAAGAT-3' Reverse 5'-GGTGAAGCGGCCAGGA-
GACGAG-3'.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-8-189-S2.doc]BMC Cancer 2008, 8:189 http://www.biomedcentral.com/1471-2407/8/189
Page 16 of 16
(page number not for citation purposes)
expression profiling predicts clinical outcome of breast can-
cer.  Nature 2002, 415(6871):530-536.
2. Bos JL: ras oncogenes in human cancer: a review.  Cancer Res
1989, 49(17):4682-4689.
3. Malaney S, Daly RJ: The ras signaling pathway in mammary
tumorigenesis and metastasis.  J Mammary Gland Biol Neoplasia
2001, 6(1):101-113.
4. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F,
Eppenberger U: Potential prognostic value of mitogen-acti-
vated protein kinase activity for disease-free survival of pri-
mary breast cancer patients.  Int J Cancer 2000, 89(4):384-388.
5. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey
RW, Robertson JF, Nicholson RI, Ellis IO: Expression and co-
expression of the members of the epidermal growth factor
receptor (EGFR) family in invasive breast carcinoma.  Br J
Cancer 2004, 91(8):1532-1542.
6. Sapi E: The role of CSF-1 in normal physiology of mammary
gland and breast cancer: an update.  Exp Biol Med (Maywood)
2004, 229(1):1-11.
7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL:
Human breast cancer: correlation of relapse and survival
with amplification of the HER-2/neu oncogene.  Science 1987,
235(4785):177-182.
8. Normanno N, Bianco C, De Luca A, Salomon DS: The role of EGF-
related peptides in tumor growth.  Front Biosci 2001,
6:D685-707.
9. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi
H, Karakas B, Blair BG, Lin C, et al.: The PIK3CA gene is mutated
with high frequency in human breast cancers.  Cancer Biol Ther
2004, 3(8):772-775.
10. Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordensk-
jold B, Rutqvist LE, Skoog L, Stal O: PIK3CA mutations and PTEN
loss correlate with similar prognostic factors and are not
mutually exclusive in breast cancer.  Clin Cancer Res 2007,
13(12):3577-3584.
11. Rodriguez-Viciana P, Sabatier C, McCormick F: Signaling specificity
by Ras family GTPases is determined by the full spectrum of
effectors they regulate.  Mol Cell Biol 2004, 24(11):4943-4954.
12. White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, Karin M,
Wigler MH: Multiple Ras functions can contribute to mamma-
lian cell transformation.  Cell 1995, 80(4):533-541.
13. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J,
Beug H, Grunert S: Ras and TGF[beta] cooperatively regulate
epithelial cell plasticity and metastasis: dissection of Ras sig-
naling pathways.  J Cell Biol 2002, 156(2):299-313.
14. Rangarajan A, Hong SJ, Gifford A, Weinberg RA: Species- and cell
type-specific requirements for cellular transformation.  Can-
cer Cell 2004, 6(2):171-183.
15. Zhao JJ, Gjoerup OV, Subramanian RR, Cheng Y, Chen W, Roberts
TM, Hahn WC: Human mammary epithelial cell transforma-
tion through the activation of phosphatidylinositol 3-kinase.
Cancer Cell 2003, 3(5):483-495.
16. Schulze A, Lehmann K, Jefferies HB, McMahon M, Downward J: Anal-
ysis of the transcriptional program induced by Raf in epithe-
lial cells.  Genes Dev 2001, 15(8):981-994.
17. Nagai MA, Fregnani JH, Netto MM, Brentani MM, Soares FA: Down-
regulation of PHLDA1 gene expression is associated with
breast cancer progression.  Breast Cancer Res Treat 2007,
106(1):49-56.
18. Neef R, Kuske MA, Prols E, Johnson JP: Identification of the
human PHLDA1/TDAG51 gene: down-regulation in meta-
static melanoma contributes to apoptosis resistance and
growth deregulation.  Cancer Res 2002, 62(20):5920-5929.
19. Haegen BA Van der, Shay JW: Immortalization of human mam-
mary epithelial cells by SV40 large T-antigen involves a two
step mechanism.  In Vitro Cell Dev Biol 1993, 29A(3 Pt 1):180-182.
20. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks
MW, Weinberg RA: Creation of human tumour cells with
defined genetic elements.  Nature 1999, 400(6743):464-468.
21. Wolthuis RM, de Ruiter ND, Cool RH, Bos JL: Stimulation of gene
induction and cell growth by the Ras effector Rlf.  Embo J 1997,
16(22):6748-6761.
22. Leaner VD, Kinoshita I, Birrer MJ: AP-1 complexes containing
cJun and JunB cause cellular transformation of Rat1a fibrob-
lasts and share transcriptional targets.  Oncogene 2003,
22(36):5619-5629.
23. Yin J, Pollock C, Tracy K, Chock M, Martin P, Oberst M, Kelly K:
Activation of the RalGEF/Ral pathway promotes prostate
cancer metastasis to bone.  Mol Cell Biol 2007, 27(21):7538-7550.
24. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L,
Trono D: Self-inactivating lentivirus vector for safe and effi-
cient in vivo gene delivery.  J Virol 1998, 72(12):9873-9880.
25.  [http://nciarray.nci.nih.gov/].
26.  [http://www.ncbi.nlm.nih.gov/geo].
27. Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT,
Der CJ, Counter CM: Distinct requirements for Ras oncogene-
sis in human versus mouse cells.  Genes Dev 2002,
16(16):2045-2057.
28. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold
WR, Connors RW, Bridges AJ: A specific inhibitor of the epider-
mal growth factor receptor tyrosine kinase.  Science 1994,
265(5175):1093-1095.
29. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL,
Hook KE, Keller PR, Leopold WR, Loo JA, et al.: Specific, irrevers-
ible inactivation of the epidermal growth factor receptor
and erbB2, by a new class of tyrosine kinase inhibitor.  Proc
Natl Acad Sci USA 1998, 95(20):12022-12027.
30. Schulze A, Nicke B, Warne PH, Tomlinson S, Downward J: The tran-
scriptional response to Raf activation is almost completely
dependent on Mitogen-activated Protein Kinase Kinase
activity and shows a major autocrine component.  Mol Biol Cell
2004, 15(7):3450-3463.
31. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mecha-
nism of action of some commonly used protein kinase inhib-
itors.  Biochem J 2000, 351(Pt 1):95-105.
32. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE,
Iglehart JD, Weinberg RA: Transformation of different human
breast epithelial cell types leads to distinct tumor pheno-
types.  Cancer Cell 2007, 12(2):160-170.
33. Frank D, Mendelsohn CL, Ciccone E, Svensson K, Ohlsson R, Tycko
B: A novel pleckstrin homology-related gene family defined
by Ipl/Tssc3, TDAG51, and Tih1: tissue-specific expression,
chromosomal location, and parental imprinting.  Mamm
Genome 1999, 10(12):1150-1159.
34. Gomes I, Xiong W, Miki T, Rosner MR: A proline- and glutamine-
rich protein promotes apoptosis in neuronal cells.  J Neuro-
chem 1999, 73(2):612-622.
35. Park CG, Lee SY, Kandala G, Lee SY, Choi Y: A novel gene product
that couples TCR signaling to Fas(CD95) expression in acti-
vation-induced cell death.  Immunity 1996, 4(6):583-591.
3 6 . T o y o s h i m a  Y ,  K a r a s  M ,  Y a k a r  S ,  D u p o n t  J ,  L e e  H ,  L e R o i t h  D :
TDAG51 mediates the effects of insulin-like growth factor I
(IGF-I) on cell survival.  J Biol Chem 2004, 279(24):25898-25904.
37. Hayashida N, Inouye S, Fujimoto M, Tanaka Y, Izu H, Takaki E,
Ichikawa H, Rho J, Nakai A: A novel HSF1-mediated death path-
way that is suppressed by heat shock proteins.  Embo J 2006,
25(20):4773-4783.
38. Hossain GS, van Thienen JV, Werstuck GH, Zhou J, Sood SK, Dick-
hout JG, de Koning AB, Tang D, Wu D, Falk E, et al.: TDAG51 is
induced by homocysteine, promotes detachment-mediated
programmed cell death, and contributes to the cevelopment
of atherosclerosis in hyperhomocysteinemia.  J Biol Chem 2003,
278(32):30317-30327.
39. Joo JH, Liao G, Collins JB, Grissom SF, Jetten AM: Farnesol-induced
apoptosis in human lung carcinoma cells is coupled to the
endoplasmic reticulum stress response.  Cancer Res 2007,
67(16):7929-7936.
40. Hinz T, Flindt S, Marx A, Janssen O, Kabelitz D: Inhibition of pro-
tein synthesis by the T cell receptor-inducible human
TDAG51 gene product.  Cell Signal 2001, 13(5):345-352.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/189/pre
pub